🇺🇸 FDA
Pipeline program

OXALIPLATIN , Placebo to MK-3475, CAPECITABINE , CALCIUM FOLINATE , FLUOROURACIL , CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL

MK-3475-585

Phase 3 small_molecule active

Quick answer

OXALIPLATIN , Placebo to MK-3475, CAPECITABINE , CALCIUM FOLINATE , FLUOROURACIL , CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL for Gastric and gastroesophageal junction (GEJ) adenocarcinoma is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Gastric and gastroesophageal junction (GEJ) adenocarcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials